Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 October 2020 | Story Leonie Bolleurs | Photo Supplied
Kyla Dooley, runner-up in this year’s Three-minute thesis competition, wants to pursue a career working alongside police enforcement, using her knowledge of forensics to solve criminal cases and convict perpetrators.

When rapes and sexual assaults are committed, DNA evidence can play a large role in convicting the offenders. DNA evidence collected from sexual crimes can, according to Kyla Dooley, often be tricky to analyse.

Kyla has just completed her master’s degree, specialising in Forensic Genetics, at the University of the Free State (UFS). She not only thrives in this field – graduating at the top of the Faculty of Natural and Agricultural Sciences in 2018 when she was awarded the Dean’s Medal – but her work also brought her the runner-up position in this year’s Three-minute thesis competition. 

She talked about her research on the use of male-specific DNA in the analysis of DNA evidence collected after crimes of a sexual nature have been committed.

Explaining her research, Kyla elaborates: “In most cases, the victim is female, while the offender is male. Therefore, the evidence is often a mixture of male and female DNA and this can make it difficult to analyse the male DNA and match it to a male suspect.”

She believes the solution to this is to target male-specific DNA in analysis. “This eliminates all female DNA and simplifies the process,” says Kyla.

“Unfortunately, male-specific DNA technology is not currently used in South Africa, because the DNA regions tested to date haven’t shown much success in distinguishing between males in our population,” Kyla points out.

“The goal is now to use DNA evidence, to match it to a suspect, and have the confidence that it came from him and only him. Or else defence lawyers could argue that it came from someone else in the population,” she says.

Improving DNA evidence

Therefore, Kyla’s research focused on evaluating a new group of male-specific DNA regions, which are to be tested yet, to see if it would be a viable option for use in South Africa. 

“I achieved this by collecting DNA samples from men on campus, processing them to obtain DNA profiles, and then determining how well these regions can distinguish between the men. The results of my research demonstrate the potential of these DNA regions to improve the use of DNA evidence when investigating sexual assaults in South Africa,” says Kyla.

She believes her study can play a role in increasing the conviction rate of sexual offenders, which could lead to a reduction in South Africa’s alarmingly high rape statistic. 

“Everyone in South Africa is affected by this horrific crime in some way or another, so the benefits of this would be widespread,” she says.

Solving crimes

Although Kyla will one day pursue further studies, she is ready for the next stage in her life. “I am in the process of applying for jobs and getting ready to dive into the real world. I’ll definitely be pursuing a career working alongside police enforcement to solve criminal cases and convict perpetrators of such crimes. Working for the NYPD in the USA or Scotland Yard in the UK is the ultimate dream job,” she says.

“I chose my field not only because the forensics world absolutely fascinates me, but also because I want to make a difference. I want to play a role in getting justice for those affected by violent crimes. One simple process in a forensic scientist’s everyday routine could be a life changer for a victim of crime,” believes Kyla.

 

 


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept